Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Acadian Asset Management LLC

Acadian Asset Management LLC grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 11,074.7% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 179,019 shares of the medical equipment provider’s stock after purchasing an additional 177,417 shares during the period. Acadian Asset Management LLC’s holdings in Hologic were worth $13,947,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Intech Investment Management LLC boosted its holdings in shares of Hologic by 4.3% in the 1st quarter. Intech Investment Management LLC now owns 40,687 shares of the medical equipment provider’s stock valued at $3,172,000 after buying an additional 1,667 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its stake in Hologic by 0.4% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 292,378 shares of the medical equipment provider’s stock worth $22,490,000 after purchasing an additional 1,136 shares during the period. Banco Santander S.A. acquired a new stake in Hologic during the 1st quarter worth $344,000. Lindenwold Advisors INC boosted its stake in Hologic by 24.2% during the 1st quarter. Lindenwold Advisors INC now owns 30,930 shares of the medical equipment provider’s stock worth $2,411,000 after purchasing an additional 6,031 shares during the period. Finally, Leo Wealth LLC boosted its stake in Hologic by 40.7% during the 1st quarter. Leo Wealth LLC now owns 6,335 shares of the medical equipment provider’s stock worth $494,000 after purchasing an additional 1,833 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of recent research reports. Stephens initiated coverage on shares of Hologic in a research note on Thursday, June 27th. They set an “overweight” rating and a $87.00 price target for the company. Evercore ISI reduced their target price on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a research note on Tuesday, July 2nd. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Friday, May 3rd. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Finally, Argus raised their target price on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.55.

Hologic Trading Up 0.6 %

HOLX traded up $0.45 during trading on Friday, hitting $78.11. 1,660,498 shares of the company’s stock were exchanged, compared to its average volume of 1,489,154. The stock has a 50 day moving average price of $74.26 and a 200 day moving average price of $74.82. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $82.45. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The firm has a market cap of $18.23 billion, a P/E ratio of 39.85, a price-to-earnings-growth ratio of 2.60 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.06 earnings per share. As a group, analysts expect that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The disclosure for this sale can be found here. 1.75% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.